Skip to main content
main-content

Heart failure

News

25-11-2020 | Empagliflozin | News

Empagliflozin LV remodeling not reliant on glucose lowering

The EMPATROPISM trial, which enrolled people without type 2 diabetes, shows reversal of left ventricular remodeling in patients with heart failure and reduced ejection fraction given empagliflozin rather than placebo.

19-11-2020 | Heart failure | News

Targeting fat mass, central adiposity may reduce HF risk in type 2 diabetes

The risk for heart failure falls significantly with reductions in fat mass and waist circumference in overweight or obese people with type 2 diabetes, shows an analysis of data from the Look AHEAD trial.

18-11-2020 | Heart failure | News

Empagliflozin shows heart failure benefits regardless of HbA1c

Empagliflozin reduces the risk for adverse cardiovascular outcomes in people with heart failure and a reduced ejection fraction irrespective of their baseline glycated hemoglobin level, EMPEROR-Reduced trial data show.

Read more

Opinion

14-11-2018 | Cardiovascular outcomes | Editorial | Article

What have I learned from cardiovascular outcome trials?

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future.

13-02-2018 | Older adults | Editorial | Article

Does setting treatment targets risk the overtreatment of type 2 diabetes in older patients?

The drive to achieve lower HbA1c targets in older patients is not without concern or risk. Our UK Board address concerns highlighted by recent trials and discuss whether current guidelines do enough to mitigate the risks of overtreatment.

22-11-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

In depth

16-11-2018 | Dapagliflozin | Video | Article

Researcher comment: DECLARE-TIMI 58

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

10-11-2018 | Dapagliflozin | Video | Article

Expert commentary: DECLARE-TIMI 58

Miles Fisher talks to medwireNews about the results of the dapagliflozin cardiovascular outcomes trial DECLARE-TIMI 58.

Journal articles and book chapters

08-11-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

23-06-2018 | Cardiovascular outcomes | Review | Article

Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists

Scheen AJ. Diabetes Res Clin Prac 2018; 143: 88–100. doi: 10.1016/j.diabres.2018.06.008

22-06-2018 | Hypertension | Review | Article

The optimal blood pressure target in diabetes mellitus: A quest coming to an end?

Papadopoulou E et al. J Hum Hypertens 2018. doi: 10.1038/s41371-018-0079-5

Image Credits